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STUDY PROTOCOL Open Access
Glutamatergic medication in the treatment
of obsessive compulsive disorder (OCD)
and autism spectrum disorder (ASD) –
study protocol for a randomised controlled
trial
Alexander Häge1*, Tobias Banaschewski2, Jan K. Buitelaar3, Rick M. Dijkhuizen4, Barbara Franke5, David J. Lythgoe6,
Konstantin Mechler1, Steven C. R. Williams6, Ralf W. Dittmann1 and the TACTICS Consortium
Abstract
Background: Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that
emerge in childhood or adolescence. Despite the effectiveness of serotonergic compounds in the treatment of
obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to 60 % of patients present a
pressing clinical problem. There are currently no medications that effectively treat the core impairments of autism
spectrum disorder. There is an urgent need for the development of conceptually novel pharmacological strategies.
Agents targeting glutamate neurotransmission, such as memantine, represent promising candidates. This proof-of-
concept clinical study will allow pilot-testing of memantine for both clinical effectiveness and tolerability/safety.
Memantine is an N-methyl-D-aspartate receptor antagonist, approved for the treatment of Alzheimer’s dementia in
a number of countries.
Methods/Design: This 12-week study has an add-on, randomised, double-blind, placebo-controlled design of
treatment with memantine, including an up-titration phase (forced flexible dose design, 5–15 mg/day), in patients
aged 6–17 years and 9 months with obsessive-compulsive disorder or autism spectrum disorder.
It is planned to include patients with obsessive-compulsive disorder (N = 50) or autism spectrum disorder (N = 50)
across four centres in three European countries. Patients will be randomly assigned to memantine or placebo in a
1:1 ratio. Primary objectives are the investigation of the effectiveness of memantine in paediatric patients for
improving symptoms of compulsivity (primary outcome measure: total score on the Children’s Yale-Brown
Obsessive-Compulsive Scale) and to explore its tolerability and safety. Secondary objectives are to explore the
effects of memantine at the level of structure, function and biochemistry of the fronto-striatal circuits, and to collect
blood for genetic analyses and biomarkers. Tertiary objectives are to explore the role of new candidate genes and
pathways for compulsivity by linking genes to clinical phenotypes, response to treatment, neurocognitive test
performance, and key structural and functional neuroimaging measures of the fronto-striatal circuits and to explore
biomarkers/proteomics for compulsivity traits.
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Discussion: This study is part of the large, translational project TACTICS (http://www.tactics-project.eu/) that is
funded by the European Union and investigates the neural, genetic and molecular factors involved in the
pathogenesis of compulsivity. Its results will provide clinically relevant solid information on potential new
mechanisms and medication treatment in obsessive-compulsive and autism spectrum disorders.
Trial registration: EudraCT Number: 2014-003080-38, date of registration: 14 July 2014.
Keywords: Glutamate, Memantine, Obsessive-compulsive disorder, Autism, Pilot trial, Psychopharmacology, Child
and adolescent psychiatry
Background
Compulsivity is a cross-disorder trait underlying pheno-
typically distinct psychiatric disorders that emerge in
childhood or adolescence. Compulsivity is defined as the
repetitive, irresistible urge to perform a behaviour, the
experience of loss of voluntary control over this intense
urge, the diminished ability to delay or inhibit thoughts
or behaviours, and the tendency to perform repetitive
acts in a habitual or stereotyped manner [1]. Obsessive
compulsive disorders (OCD) are characterised by repeti-
tive thoughts, impulses or images (obsessions) and re-
petitive behaviours or mental acts (compulsions) [2] and
typically have onset in late childhood or early adoles-
cence and mid-adulthood [3, 4]. Autism spectrum disor-
ders (ASD) are characterised by persistent deficits in (1)
social communication and social interaction across mul-
tiple contexts, and by (2) restricted, repetitive patterns
of behaviour, interests or activities. ASD have their onset
prior to age 3 years, and a strong persistence over time
in childhood, over adolescence and into adulthood [2].
This study is part of a large, translational project funded
by the European Community's Seventh Framework
Programme (FP7/2007-2013) under grant agreement num-
ber 278948, TACTICS (Translational Adolescent and
Childhood Therapeutic Interventions in Compulsive
Syndromes). It aims to identify the neural, genetic and mo-
lecular factors involved in the pathogenesis of compulsivity
(http://www.tactics-project.eu/).
Compulsivity and compulsivity-associated disorders
Compulsivity and the closely associated impulsivity trait
are characterised by behavioural disinhibition main-
tained by maladaptive fronto-striatal brain circuits [5].
Current neuroanatomical models posit the existence of
separate but intercommunicating compulsive and impul-
sive fronto-striatal circuits, differentially modulated by
neurotransmitters [5]. In the compulsive circuit, a stri-
atal component (caudate nucleus) may drive compulsive
behaviours and a prefrontal component (orbitofrontal
cortex, OFC) may exert inhibitory control over them. In-
creased activity within the striatal components or de-
creased activity in the prefrontal components may thus
result in an increased automatic tendency for executing
impulsive or compulsive behaviours, depending on the
sub-component affected. Childhood OCD has recently
been associated with decreased prefrontal activity [6], fit-
ting with reduced prefrontal control over the striatum.
Interestingly, glutamatergic imbalance in fronto-striatal
regions has also been observed in childhood OCD [7].
Furthermore, earlier work has shown reduced volume of
the striatum in children with ASD that relates to repeti-
tive and compulsive behaviours [8, 9].
Glutamatergic mechanisms and fronto-striatal circuits
The fronto-striatal circuits implicated in compulsivity
and impulsivity are notable for their relatively rich gluta-
matergic receptor density [10]. Moreover, glutamate
modulates the metabolism and function of the fronto-
striatal circuits. Glutamatergic projections to and from
the various frontal sub-regions (OFC, infralimbic cortex
and prelimbic cortex) to the striatum play a key role in
the regulation of various compulsive behaviours in
humans including: (1) the feeling of loss of control
(OCD), (2) repetitive motor behaviours (stereotypy in
ASD), and (3) a maladaptive habitual pattern (addiction).
Neuroimaging studies have confirmed that glutamatergic
projections between the various frontal sub-regions and
the striatum play a key role in the regulation of compul-
sive behaviours in humans ([10, 11]. Compulsivity has
been associated with increased glutamatergic activity in
the striatum and the anterior cingulate cortex in clinical
magnetic resonance spectroscopy (MRS) studies [11].
Glutamatergic medication in the treatment of
compulsivity/impulsivity
Despite the effectiveness of serotonergic compounds in
the treatment of OCD, treatment-resistant symptoms
remaining in 40 to 60 % of patients present a pressing
clinical problem [12–14]. Thus, there is an urgent need
for the development of conceptually novel pharmaco-
logical strategies. Consistent with the hypothesis of the
role of glutamatergic dysregulation in the pathophysi-
ology of OCD, agents targeting glutamate neurotrans-
mission, such as memantine (and riluzole), represent
promising candidates (e.g. [13–17]). Open-label studies
in children and adults have provided supportive evidence
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for the effectiveness of these glutamate-modulating com-
pounds for OCD symptoms [12, 13, 18–22]. There are
currently no drugs that have been shown to effectively
treat the core impairments of ASD. Although studies of
serotonin reuptake inhibitors and atypical antipsychotics
have suggested improvement of repetitive behaviour in
ASD, this has yet to be proven in placebo-controlled tri-
als [23–25]. Emerging evidence from neuroimaging stud-
ies suggests: individuals with ASD show an imbalance of
excitatory (glutamate) and inhibitory neurotransmitters
(gamma-aminobutyric acid (GABA)). Such regionally
specific abnormalities in glutamatergic neurotransmis-
sion may vary across the lifespan [26, 27]. Ghanizadeh
reviewed investigations of amino acid levels in plasma,
serum and cerebrospinal fluid (CSF) from ASD patients
and reported both increased levels of glutamate and
homocysteine and decreased levels of glutamine and
tryptophan [28].
Systematic literature review and choice of investigational
compound
A systematic literature review (Mechler et al., in prepar-
ation) has recently been performed within the TACTICS
network, in preparation for this exploratory ‘Glutamater-
gic medication in the treatment of Obsessive Compulsive
Disorder and Autism Spectrum Disorder’ (GOAT) trial. It
focused on the evaluation of glutamatergic substances
with potential benefit for the treatment of paediatric
patients in multi-centre studies aiming at compulsivity-
related disorders. In summary, there were a total of 21 tri-
als (paediatric randomised controlled trials and open-label
trials). Six substances were evaluated: D-cycloserine,
memantine, minocycline, modafinil, N-acetylcysteine, and
riluzole. The most substantial information appeared to be
available for the compound memantine. Memantine is an
N-methyl-D-aspartate (NMDA) antagonist, clinically used
as a ‘cognitive enhancer’, regulatory-approved for the treat-
ment of Alzheimer’s dementia in a number of countries. It
has successfully been used and further been studied in
children diagnosed with ASD for the treatment of cognitive,
behavioural, and memory dysfunctions, in open-label and
controlled trials [29–31]; cf. a recent clinical development
program (memantine) sponsored by Forest Laboratories/
Merz Pharmaceuticals, www.clinicaltrials.gov). Memantine
has also been explored for the treatment of attention
deficit/hyperactivity disorder (ADHD) (e.g. [32]). However,
additional research examining the efficacy/effectiveness and
tolerability/safety of memantine, e.g. placebo-controlled
clinical trials, is needed. Findings on memantine suggested
clinical effectiveness in ASD and OCD symptomatology
and appeared to offer the best risk-benefit profile for
multi-centre trials with paediatric patients suffering from
compulsivity-related disorders. Considering the current
state of knowledge and assessing available findings on
effectiveness, tolerability/safety and feasibility of study im-
plementation, the subgroup of experts in paediatric psy-
chopharmacology from the TACTICS consortium jointly
decided to apply the compound memantine for this paedi-
atric pilot study.
Molecular-genetic factors involved in compulsivity, in
ASD and OCD
Compulsivity-related disorders such as OCD and ASD
are assumed to be highly heritable but genetically com-
plex, with multiple genetic variants of small effect con-
tributing to disease in most patients [33]. Genes
encoding the SLC1A1, SLC1A2 and SLC1A3 glutamate
transporters are candidate genes for both OCD and
ASD [34]. Genes encoding the NMDAR1 [35] and
NMDAR2A [36] subunits of the postsynaptic NMDA
glutamate receptor are associated with ASD and those
encoding the NMDAR2B subunit with paediatric OCD
[37]. Novel approaches are needed to facilitate the iden-
tification of genetic risk factors for brain disorders and
related traits, like compulsivity. One such approach is
the study of intermediate phenotypes [38]. It has been
shown that using intermediate phenotypes indeed did
improve the chance of establishing significant findings
in genetic studies [39–41].
Biomarkers – proteomics of compulsivity and associated
disorders
Symptoms of compulsivity-associated disorders such as
OCD, ASD and ADHD frequently co-occur in the same
patients [42]. Quantitative and molecular genetics, cog-
nitive and imaging studies indicate that this clinical
overlap is due to common genetic factors and/or
common underlying neural and molecular mechanisms
(review, see [43]). Indeed, it has been shown that alter-
ations in brain development, mitochondrial function,
immune system and oxidative stress pathways as well as
dysfunctions in neurotransmitter systems may be in-
volved in several or all of these disorders [44–47]. The
biological determinants that contribute to the pathogen-
esis of these conditions, however, are poorly defined,
and currently, no well-characterised biomarkers are
available. One major positive impact of this study – as
integral part of the TACTICS project – may lead to a
greater insight into the molecular mechanisms involved
in the development of compulsivity and compulsivity-
associated disorders and potentially facilitate the devel-
opment of much needed differential diagnostics,
improved drug discovery and clinical development, and
designs based on biomarker-based segmentation of pa-
tients. This may allow for earlier diagnosis and persona-
lised medicine strategies for more effective treatments in
the future [48–51].
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Aims and objectives
Primary objectives
To investigate: clinical effectiveness of the glutamatergic
compound memantine in paediatric patients with OCD
(GOAT-1) and ASD (GOAT-2) with respect to symptoms
of ‘compulsivity’ (assessed as total score of the Children’s
Yale-Brown Obsessive-Compulsive Scale (CY-BOCS;
[52])) and to explore tolerability and safety (based on, e.g.
laboratory measures, electrocardiography (ECG), adverse
events) of the compound memantine in these clinical
indications.
Secondary objectives
To explore: the effects of glutamatergic interventions at
the level of structure, function and biochemistry of the
fronto-striatal circuits (magnetic resonance imaging
(MRI), MRS), in subgroups (e.g. disorders, age range).
To collect: blood for genetic analyses and biomarkers.
To explore: additional clinical outcomes, disorder-specific
outcomes (e.g. core symptoms, response rates, social
functioning).
Tertiary objectives
To explore: the role of new candidate genes and pathways
for compulsivity by linking genes to clinical phenotypes, neu-
rocognitive test performance, and key structural and func-
tional neuroimaging measures of the fronto-striatal circuits.
To explore: biomarkers/proteomics for compulsivity
traits.
Methods/design
This study is a multi-national, multi-centre, randomised,
double-blind, parallel, placebo-controlled add-on trial with
three study periods: study period I will be a 2-week
screening (and washout) period, study period II will be a
12-week double-blind, randomised, placebo-controlled
period, and study period III will be a double-blind 1-week
down-titration period. Study medication (memantine or
placebo) will be added to regular treatment for the re-
spective disorders. Male and female patients (N = 50 per
disorder, i.e. OCD, ASD), will be randomised into study
period II. Patients who complete study period II will par-
ticipate in study period III. The study visit intervals (sug-
gested and allowed) for the three study periods are
outlined in detail as part of the schedule of events (SOE)
(Table 1).
Participating sites
Participating sites are Mannheim (Department of Child and
Adolescent Psychiatry and Psychotherapy, Central Institute
of Mental Health), Germany; London (Departments of
Neuroimaging and Child and Adolescent Psychiatry,
Institute of Psychiatry, Psychology and Neuroscience, King’s
College London), United Kingdom; Nijmegen (Karakter
Child and Adolescent Psychiatry, Donders Institute for
Brain, Cognition and Behaviour, Radboud University
Medical Center), The Netherlands and Utrecht (Depart-
ment of Child and Adolescent Psychiatry, Brain Center
Rudolf, University Medical Center Utrecht), The
Netherlands.
Information and consent procedure
Subjects and their parents will be asked to participate in
this study by one of the (sub-) investigators. They will
receive a letter/informed consent document explaining
the study (in their local language). All children and ado-
lescents will also receive a respective letter/informed
assent document about the study, with the (complexity
of the) language suitably adapted. After an adequate time
interval, the subjects’ parents will be contacted again. If
subjects require more time to consider participating, as
much time as is necessary will be allowed. Informed
consent and assent will be obtained from all guardians
and participants before inclusion. If the patients and par-
ents decide to participate, a brief screening will be con-
ducted, e.g. on the telephone, to check for any major
exclusion criteria. If after this brief screening the subject
is included in the study, they will receive a set of ques-
tionnaires at home. Parents will be asked to fill out these
forms and return these to the centre.
Study period I (screening period with washout)
Study period I is a 2-week screening and washout period
(visits 1–2); during this period, patients will be screened
for study eligibility. Before or at the day of visit 1, the
study will be explained to the patient and his or her par-
ent or legal guardian, who will then sign and date the in-
formed consent and assent documents (International
Classification of Diseases (ICD); as adequate according
to the legal requirements in the respective country). The
ICD must be signed before any study procedures are
conducted and before patients discontinue any excluded
medications.
Screening for eligibility begins at visit 1. If the patient
is eligible, the patient will enter the washout phase dur-
ing which all excluded medications will be tapered off
and stopped entirely by visit 2 (for the respective com-
pounds, the medication-free period should be at least
five half-lives in duration). Randomisation to active drug
or placebo will occur at visit 3. At visit 1, patients will
undergo psychiatric screening tests and safety screening
procedures. A patient history will also be taken. See the
study SOE (Table 1) for a complete list of study period I
procedures. All criteria for enrolment, including the
ECG and laboratory analyses, will be verified prior to
randomisation at visit 3. At visits 2 and 3, patients will
be further evaluated by the clinical research team as
shown in the study SOE (Table 1).
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Table 1 Schedule of events
Study period (SP) SP I
(screening/ washout)
SP II
(double-blind treatment)
SP III
(down-titration)
Visit number: 1 2 3 4 5 6 7 8 9 10 Unscheduled visitsa Early discontinuation
(End of) week: −2 −1 0 1 2 4 6 8 12 13
Suggested time to next visit (days): 7 7 7 7 14 14 14 28 7
Allowable time to next visit (days): 5–9 5–9 5–9 5–9 10 - 18 10–18 10–18 24–32 5–9
Clinical assessments:
Informed consent/assent X
Psychiatric assessment X
Systematic Interview, e.g. DISC (OCD group) X
Systematic Interview, e.g. DISC (re co-morbidities):
ODD, CD, tic domains (all patients)
X
ADI-R short version, (ASD group) X
WIS-C (4 subtests) X
Inclusion/exclusion criteria X X X
Randomisation to active drug vs. placebo X
Demographics X
Physical examination X
Medical history X
Discontinuation of prohibited medications X
Height, weight, vital signs X X X
Clinical laboratory testsb,c, X Xc X Xc (X)a Xc
Serum and urine pregnancy testd X
Urine drug screen X (X)a X
Urine analysis X X X X X
Biomarkers X
Genetics X
Physical Development Scale X X
CGI-S X X X X X X X X X X
CGI-I X X X X X X X X
C-GAS X X X X
CBCL, 6–18 X
CY-BOCS X X X X X X X X (X)a X
Children’s Social Behaviour Questionnaire X X X X X X X X (X)a X
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Table 1 Schedule of events (Continued)
Repetitive Behaviour Scale-Revised (RBS-R), X X X X X X X X (X)a X
CHIP-CE/AE X X X X
PAERS X X X X X X X X X X
Neuropsychological test battery X X X
Neuroimaging assessments X X
AE monitoring X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X
Eligibility to remain in study X X X X X X X X X X X
Study drug dispensed X X X X X X X
Study drug returned X X X X X X X
alaboratory tests, ECG, etc. at unscheduled visits (due to AEs) according to the discretion of the investigator
bpatients with significant increase after baseline (visit 3) in AST, ALT, total bilirubin, or AP from the upper limit of the lab reference range will have additional lab testing and/or consultation
cto be collected in a fasting state at visits 3 and 9 (and early discontinuation, if possible); fasting defined as at least 8 hours with water as the only oral consumption
dfemales of child-bearing potential only; additional pregnancy tests possible at each visit at the discretion of the investigator
AE adverse event, ASD autism spectrum disorders, AST aspartate aminotransferase, ALT alanine aminotransferase, AP alkaline phosphatase, CBCL Child Behaviour Checklist, C-GAS Children’s Global Assessment, CGI-I,
Clinical Global Impression-Improvement, CGI-S Clinical Global Impression-Severity, CHIP-CE/AE Child Health and Illness Profile, CY-BOCS Children’s Yale-Brown Obsessive-Compulsive Scale, DISC Diagnostic Interview for
Children, ECG electrocardiography, OCD obsessive-compulsive disorder, PAERS Pediatric Adverse Event Rating Scale
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Study period II (acute period)
Study period II is a 12-week, randomised, double-blind,
and placebo-controlled add-on acute treatment period
(visits 3–9). At baseline (BL), patients will randomly be
assigned to active drug or placebo in a 1:1 ratio. In order
to safeguard patients in the study, patients can be either
in outpatient or inpatient status. For patients in both the
active drug treatment group and in the placebo group,
dosage will be given depending on the patient’s weight,
and will be up-titrated according to Table 2. Visit 7 will
be performed via a telephone interview with assessments
of effectiveness and tolerability/safety (no physical exam-
ination, ECG, blood draws, etc.); if needed from a clin-
ical perspective ‘unscheduled visits’ will be performed,
based on investigator judgment.
Study period III (double-blind down-titration period)
Study period III is a 1-week double-blind down-titration
period (visits 9–10) from study medication, active drug or
placebo. Any patient who completes study period II (visit 9)
will continue into study period III. In a blinded fashion,
their dose of study medication will be titrated down de-
pending on their final dose in study period II. Placebo-
treated patients from study period II will continue placebo
treatment in study period III. In order to maintain the
blind, all patients will receive the respective amounts (e.g.
number of tablets) of study drug (active or placebo). The
final visit of this period will be visit 10. See the SOE for the
timing of events and the measures to be assessed (Table 1).
Study population
Overall, N = 100 patients (N = 50 participants with OCD
and N = 50 participants with ASD), male or female, with
inpatient or outpatient status, aged 6 years (ASD pa-
tients)/8 years (OCD patients) to 17 years and 9 months
at inclusion, will be randomised into study period II.
These patients will be recruited from four centres, i.e. per
site approx. N ≥24 children and adolescents (N = 12–13
with OCD; 12–13 with ASD).
Inclusion criteria
General inclusion criteria for both patient groups (OCD
and ASD):
 Male or female patients
 Inpatient or outpatient status
 Aged 6 years (ASD patients)/8 years (OCD patients)
to 17 years 9 months at initial inclusion
 IQ ≥70 (based on Wechsler scales, four subtests)
 Clinical Global Impressions-Severity (CGI-S; [53, 54])
score ≥4 (moderately ill; anchored to respective
disorder) at BL (visit 3)
 Ability to speak and comprehend the native language
of the country in which the assessments take place
 Signed informed consent by parents or legal
representatives
 Signed informed assent by patients (indicating that
the subject is aware of the investigational nature and
the core aspects of the study and the study is run in
accordance with the International Conference on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
Good Clinical Practice (GCP) guideline E6 (1996)
 Female subject must not have a positive beta-
HCG pregnancy test at screening, and must have
a negative urine pregnancy test at BL, and agree
to comply with applicable contraceptive
requirements
Inclusion criteria for subjects with OCD (GOAT-1):
 Diagnostic and Statistical Manual, 5th edition
(DSM-5) diagnosis of OCD [2], according to a
structured interview (e.g. DISC; [55])
Inclusion criteria for subjects with ASD (GOAT-2):
 DSM-5 diagnosis of ASD [2], according to the
Autism Diagnostic Interview-Revised (ADI-R; [56])
Exclusion criteria
General exclusion criteria for all subject groups:
 Intellectual disability (IQ <70)
 Body weight below 20 kg at BL
 Major physical illness of the cardiovascular,
endocrine, pulmonary, or the gastrointestinal system
Table 2 Memantine dosing schedule in mg/day by body weight; study period II
Dose range (mg/day)a of distributed medication at … (for weeks …):
Screening/Baseline Weight (kg) V3 (wk 1) V4 (wk 2) V5 (wks 3–4) V6 (wks 5–8) V8 (wks 9–12) b V9 (wk 13) (discontinuation)
≥60 5 10 15 15 15 10→ 5→ 0
40–59 5 10 10 10 10 5→ 0
20–39 5 5 5 5 5 5→ 0
Dose titration aims at target doses as indicated in the table, based on clinical judgment.
aDosage may be adjusted upwards and downwards by 5 mg/day increments within the range shown for each weight group at indicated visits/dates
bDose should remain stable during the last 4 weeks of study period II (weeks 9–12), unless a dose reduction is necessary for tolerability or safety reasons, based
on clinical judgment
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 Contra-indications for memantine, according to the
Summary of Product Characteristics (SPC)
 History of or present clinically relevant somatic
acute or chronic disorder that, in the opinion of the
investigator, might confound the results of
tolerability/safety assessment, or prohibit the
patients from completing the study, or would not be
in the best interest of the patient
 Subject has failed to respond, based on investigator
judgment, to an earlier adequate course (dose and
duration) of the investigational drug therapy,
memantine
 Subject has a documented allergy, hypersensitivity,
or intolerance to, memantine
 Subject has a positive urine drug screen result at
screening or BL (apart from earlier prescribed
medication; retest and negative result at BL needed
then)
 Subject has taken another investigational product or
taken part in a clinical study with 30 days prior to
screening
 Subject is female and is pregnant or lactating
 For those subjects intending to participate in the
neuroimaging assessments: all contra indications for
MRI assessment, such as the presence of metal
objects in or around the body (e.g. pacemaker,
dental braces)
 Patients/parents will not be excluded from the study
if they do not agree to participate in certain sets of
assessments (e.g. neuroimaging, blood sampling for
bioanalytical analyses)
Randomisation
Randomisation will be done in a 1:1 ratio (active drug:
placebo).
Sample size calculation
The total sample size of approx. N = 100 paediatric pa-
tients (N = 50 in each diagnostic subgroup (OCD, ASD))
across trials will not allow for confirmatory statistical
analyses but will be adequate for descriptive statistics,
for pilot-testing of the chosen glutamatergic medication
(memantine), and for hypothesis generation.
Endpoints
The endpoint for primary objective 1 (clinical effective-
ness) is the baseline-to-endpoint change of compulsivity
as measured by the CY-BOCS total score (all patients).
The endpoints for primary objective 2 (tolerability and
safety) are adverse event (AE) rates, derived from both
spontaneous reporting and a structured AE instrument,
the (adapted) Pediatric Adverse Event Rating Scale
(PAERS; [57]).
The endpoints for the secondary objectives (other ef-
fects) are additional clinical outcomes, e.g. response rates,
response defined as at least 30 % reduction versus BL on
the primary outcome scale (CY-BOCS total score, for
OCD, ASD patients) plus Clinical Global Impressions-
Improvement (CGI-I; [53, 54]) score of 1 (very much im-
proved) or 2 (much improved); baseline-to-endpoint
changes in the total score of the Aberrant Behaviour
Checklist-Community (ABC-C; [58–60]: ASD patients).
For the tertiary objective (genetic pathways) genotypes of
single common and rare variants in candidate genes, and
also combined genetic variants in whole genes or neuro-
transmitter systems/gene pathways will be investigated and
further laboratory assessments of various proteins in blood
plasma will be performed. Neuroimaging data will be ana-
lysed according to the TACTICS COMPULS protocol (see
below) in order to explore the effects of glutamatergic inter-
ventions at the level of the structure, function and bio-
chemistry of the fronto-striatal circuits.
Measures
Diagnostic instruments
Diagnostic Interview for Children (DISC) In order to
determine diagnoses of OCD, e.g. the Diagnostic Inter-
view for Children (DISC; [55]) will be used and adminis-
tered by trained investigators. In order to assess most
common co-morbidities, the modules for tic disorder,
oppositional-defiant disorder, and conduct disorder will
be applied, additionally; this interview will be completed
with parents of patients in all groups.
Autism Diagnostic Interview-Revised (ADI-R) The
Autism Diagnostic Interview-Revised (ADI-R; [56]:
adapted short version, focusing on criteria relevant for
diagnosis) will be administered by a certified interviewer
to determine the ASD diagnosis. This interview covers
the core domains of ASD.
Clinical change Rigid and compulsive patterns of be-
haviour will be measured in all participants, thus both
patient groups, using the following measures:
Aberrant Behaviour Checklist-Community (ABC-C)
The Aberrant Behaviour Checklist-Community
(ABC-C; [58, 59]) is a parent-rated 58-item scale
assessing behaviour and psychiatric symptoms across
the five domains: Irritability, Agitation and Crying,
Lethargy/Social withdrawal, Stereotypic behaviour,
Hyperactivity/Noncompliance and Inappropriate
speech.
Children’s Yale-Brown Obsessive-Compulsive Scale
(CY-BOCS)
The Children’s Yale-Brown Obsessive-Compulsive Scale
(CY-BOCS; [52]) is a clinician-rated 10-item scale, with
Häge et al. Trials  (2016) 17:141 Page 8 of 16
each item rated on a 5-point scale from 0 = ‘no symptoms’
to 4 = ‘extreme symptoms’, with, apart from a total score,
subtotals for obsessions (items 1–5) and compulsions
(items 6–10).
Children’s Social Behaviour Questionnaire (CSBQ)
The Children’s Social Behaviour Questionnaire (CSBQ;
[61–63]) is a 49-item parent-rated questionnaire that
aims to quantify the different behavioural dimensions
along which children with ASD vary. In this study we
will use the total score and rigidity(-related) subscale
scores (e.g. Stereotyped behaviour, and Fear of and
resistance to changes).
Repetitive Behaviour Scale-Revised (RBS-R)
The Repetitive Behaviour Scale-Revised (RBS-R; [64])
is a 43-item parent-rated questionnaire for measuring
the presence and severity of a variety of forms of
restricted, repetitive behaviour. It consists of six
subscales: Stereotyped behaviour, Self-injurious
behaviour, Compulsive behaviour, Routine behaviour,
Sameness behaviour, and Restricted behaviour.
Clinical Global Impression-Severity (CGI-S)
The Clinical Global Impressions-Severity (CGI-S; [53, 54])
is a single-item rating of the clinician’s assessment of the
severity of symptoms in relation to the clinician’s total
experience with OCD or ASD patients. Severity is rated
on a 7-point scale (1 = normal, not at all ill; 7 = among the
most extremely ill subjects).
Clinical Global Impression-Improvement (CGI-I)
The Clinical Global Impressions-Improvement (CGI-I)
[53, 54] is a single-item clinician rating of the total
improvement (or worsening) of the patient’s symptoms
since the beginning of treatment regardless of whether
the improvement (or worsening) was thought to be due
entirely to the drug treatment. Improvement/worsening
is rated on a 7-point scale (1 = very much improved;
7 = very much worsened).
Children’s Global Assessment (C-GAS)
The Children’s Global Assessment Scale (C-GAS; [65])
is a global, unidimensional clinician rating of social and
psychiatric functioning in children aged 4–16 years.
Scores on the measure range from 1 (most impaired) to
100 (healthiest).
Additional measures
The Child Behaviour Checklist (CBCL, 6–18) The
Child Behaviour Checklist (CBCL, 6–18; [66] cf. [67])
will be applied – parent-reported – at BL in order to as-
sess general symptomatology (cf. SOE). It is a standard
instrument that allows evaluating various behavioural
domains in children and adolescents; it has been psycho-
metrically validated and is available in the very country
languages involved in this study. In this study, the ‘prob-
lem behaviour’ section will be applied only, not the
‘competencies’ part. It may also allow for analyses on
mediating factors for primary and secondary outcome
parameters.
Health outcomes/Quality of life measures
Child Health and Illness Profile (CHIP-CE) The Child
Health and Illness Profile (CHIP-CE) Parent Report
Form [68] has been used in a number of paediatric trials
with psychotropic medications and allows comparisons
with findings from paediatric populations with non-
psychiatric disorders. It is available in the respective
country languages involved in this study.
Safety evaluations
Spontaneous adverse event reporting Spontaneous ad-
verse event reporting will be based on standard questioning
of patients and parents by the investigator at each visit.
Pediatric Adverse Event Rating Scale (PAERS) In a
second step, the structured Pediatric Adverse Event Rat-
ing Scale (PAERS; [57]: adapted/shortened version) will
be applied at each visit, beyond standard AE reporting
solicited by open questioning, in order to systematically
collect AEs; the investigator-rated version will be used,
based on parent- and patient-information.
Only PAERS reports on ‘serious’ AEs will be added to
the ‘spontaneous reporting of AE results’ and be re-
ported immediately.
Laboratory tests
Blood and urine samples will be collected at the times
specified in the study SOE (Table 1) and when clinically
indicated. Standard laboratory tests including clinical
chemistry, electrolytes, urine analysis, and haematology
panels will be performed. Laboratory tests will be ana-
lysed by a local laboratory, at each study site. Urine drug
screening will be performed at study start and in case of
suspected intoxication, overdose, etc., at the discretion
of the investigator, at regular or unscheduled visits. If
agreed to by patients and parents, 30 ml blood will be
drawn from participants for biobanking purposes, for
DNA isolation, and assessment of biomarkers for which
either serum or plasma samples are prepared. The
venipuncture will be performed by medical staff, e.g. a
trained nurse practitioner, who has considerable experi-
ence of working with children.
Molecular-genetic material
Genome-wide genotyping of common and more rare
variants will be performed using PsychChip (or similar)
(https://sites.google.com/a/broadinstitute.org/psych-chip
-resources/home). The resulting data will be analysed in
two ways: (1) the variation in the genes will be analysed
for rare variants that appear to have deleterious effect on
gene function (based on conservation, predicted changes
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in gene-product structure and function). Those will be
studied further by protein studies; and (2) in addition to
this, gene-wide burden analyses [69] of rare as well as
common variants will be performed to identify an associ-
ation with treatment response or diagnosis. All analyses
will be corrected for multiple testing as appropriate.
Other biological material
Protein levels of blood-expressed compulsivity and addic-
tion genes will be monitored using multiplex immunoassay
profiling of peripheral blood cells and serum. This work will
be performed in close collaboration with the laboratory of
Professor S. Bahn in Cambridge/UK. In addition, at the
Nijmegen centre there are expertise and facilities for High
Pressure Liquid Chromatography (HPLC) in blood platelets
(for products of neurotransmitter pathway genes). Earlier
work has shown that potential compulsivity- and addiction-
relevant molecules such as hormones, cytokines and
neurotransmitters such as glutamate and serotonin, are
measurable in serum and blood cells.
Neuropsychological assessment
All neuropsychological tasks performed within this study
are suitable for subjects from the age of 5 years to
adulthood.
Neurocognitive assessment battery
In order to explore potential medication effects (im-
provements, impairments) to cognitive functioning, a
neurocognitive assessment battery, the Amsterdam
Neuropsychological Test Battery (ANT), will also be
used, including attentional, set-shifting, motor speed
and inhibition, cognitive flexibility, and verbal working
memory tasks.
Wechsler Intelligence Scale for Children (WISC-III)
The WISC-III will be performed in order to determine the
general IQ level of the patient if not done within 2 years
from BL [70]. Patients must have an IQ of >70 (based on,
at least four subtests, two verbal plus two performance
tests) from the Wechsler IQ Scales, e.g. WISC, WAIS. In
this study four subtests will be used, e.g. Vocabulary, Simi-
larities, Block Design, and Matrix reasoning [71]. Age-
and country-specific adaptations may be used.
Neuroimaging
If agreed to by patients and parents, neuroimaging of
the patients will be performed by MRI according to the
protocol of another TACTICS project, COMPULS. The
aim of COMPULS is to identify neural, neurocognitive,
genetic, and biomarker mechanisms underlying compul-
sive behaviours in high-risk subjects and controls. The
primary objectives are to examine whether (1) structural
and functional abnormalities of the fronto-striatal circuits
are related to the development of compulsive and impulsive
behaviour in ASD and OCD, and (2) the glutamate system
is a key modulator in these fronto-striatal circuits. The
COMPULS study has a mixed cross-sectional longitudinal
design with assessments at two time points. Measurements
are: MRI (structural MRI, functional MRI, resting state
MRI, Diffusion Tensor Imaging (DTI)), MRS (spectros-
copy), plus multiple tasks reflecting cognition and behav-
iour (cf. website: http://www.tactics-project.eu; WP04).
Vital signs
Vital signs including body temperature, heart rate
(pulse), and blood pressure will be recorded as specified
in the study SOE (Table 1).
Height and weight
Height and weight will be recorded as specified in the
study SOE (Table 1); measurements will be performed
according to standardised procedures across study sites.
Electrocardiogram (ECG)
ECGs will be performed following standard procedures
at the visits outlined in the SOE (Table 1).
Medication and dosing
The investigator or his/her designee is responsible for
explaining the correct use of the investigational agent(s)
to the patients and parents, verifying that instructions
are followed properly, maintaining accurate records of
study drug dispensing and collection, and of returning
all unused medication at the end of the study.
This study involves a comparison of an active drug
(memantine) with matching placebo. During study period
II, medication will be initiated and modified according to
the weight group of the patient at BL (visit 3). Dosing may
then be increased (or decreased) by 5 mg/day increments,
respectively, at specified visits/dates according to the
weight of the subject (cf. Table 2). Stepwise up-titration is
recommended to the target dose or the highest tolerable
dose by week 4, accordingly. Dosing should remain stable
during the last 4 weeks of study period II unless a dose re-
duction is necessary for tolerability or safety reasons. In
case of dose-adjustments due to AEs unscheduled visits
can be performed (for stepwise down-titration). Patients
who cannot tolerate the minimum daily dose specified
(5 mg/day) will be discontinued from the study. Investiga-
tor decisions on dose changes (up or down) will only be
permitted at study visits (or, due to AEs, at unscheduled
visits for down-titration). Study medication will be given
once daily in the evening, with or without food.
Based on the dosing information from the published lit-
erature and considering earlier and ongoing trials with
memantine (sponsored by the pharmaceutical company
Forest Laboratories, Berlin, Germany) in this age group,
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dosing was chosen weight-based, accordingly, also taking
into account dose-unit availability in Europe (see Table 2).
Production, packaging of the medication
All study medication will be identical in appearance and
will be dispensed to patients or their parents by trained
site personnel. A cooperation partner (H. Lundbeck A/S
Pharmaceuticals, Copenhagen, Denmark) will provide the
primary study material consisting of tablets containing 5
and 10 mg of memantine each and tablets containing pla-
cebo (in identical appearance). Study medication will be
dispensed to the patient/parent at the investigator’s study
site. Study medications will be packaged in blister packs
or bottles. Clinical trial materials will be labelled according
to the country’s regulatory requirements.
Concomitant therapy
In general, concomitant medications with primarily cen-
tral nervous system activity are not permitted in this
study. A protocol attachment contains a list of medica-
tions and classes of medications that are or are not per-
mitted during this study (depending and in accordance
with the SPC for memantine, used in GOAT-1 and
GOAT-2). Upon assent/consent by the patient and pa-
tient’s parent, the medications that are not allowed
should be tapered off and stopped by visit 2, and be
completely washed out by visit 3. Investigators should
follow clinical guidelines with respect to duration of
washout periods (minimum of five half-lives). Concomi-
tant medication will be reported with compound, length
of use, and doses in the clinical report form.
Treatment compliance
Patient compliance with study medication will be
assessed at each visit by direct questioning of parent
and/or patient. Patients/parents will be asked to return
both used (including empty) and unused blister cards
distributed on the previous visit. Any deviation from the
prescribed dosage regimen will be recorded. Final drug
accountability reconciliation will be performed at the
end of treatment or discontinuation.
During the double-blind treatment phase (study period
II), a patient will be considered significantly noncompliant
if he or she misses more than two consecutive days of study
medication (full doses), or fails to take at least 80 % of pre-
scribed doses of study medication (full doses) during two or
more visit intervals. Similarly, a patient will be considered
significantly noncompliant if he or she intentionally or re-
peatedly takes more than the prescribed amount of medica-
tion as judged by the investigator.
If a patient is noncompliant during an interval, the pa-
tient and parent will be counselled regarding the import-
ance of compliance in this study.
Statistical analysis
Clinical efficacy data
The end of the treatment phase will be taken as the primary
endpoint. Change from BL in CY-BOCS total score will be
used as the primary efficacy variable. As a secondary out-
come measure a binary response score will be composed
based on the change in CY-BOCS total score and the
Clinical Global Impression-Improvement (CGI-I) scale at
the end of the treatment phase (at least 30 % reduction in
CY-BOCS total from BL and a score of 1 (very much im-
proved) or 2 (much improved) in CGI-I scale). Additional
symptom severity scores will be used as secondary efficacy
measures.
General linear models will be applied on the CY-
BOCS change score to compare the two treatment
groups (active drug, placebo). Gender, age, investiga-
tional site and BL measurement will be included as co-
variates. Furthermore, diagnosis and diagnosis by
treatment interaction will be entered in the model. A
significant interaction effect will be followed up by sep-
arate analyses of the two diagnostic groups. In the pres-
ence of a high drop-out rate methods for missing data
(e.g. last observation carried forwards (LOCF), mixed
effect model repeat measurement (MMRM)) will be ap-
plied and sensitivity analyses will be performed to assess
whether efficacy results are stable across different ana-
lysis methods. Logistic regression analyses will be per-
formed to evaluate the effect of treatment on the binary
response score. To study the impact of moderating fac-
tors on the outcome measures general linear models
and logistic regression analyses will be applied, as ap-
propriate. Gender, age, diagnostic group and investiga-
tional site will be included as covariates in all analyses.
Multivariate statistical analysis of all data will be ap-
plied, reducing the chances of identifying false positives.
This method can incorporate different types of predic-
tors (clinical patient characteristics as well as neuro-
psychological and neuroimaging data, genetic and
protein data). All analyses will be corrected for multiple
testing as appropriate.
Tolerability/Safety data
To analyse tolerability and safety of the medication lo-
gistic regression analysis will be performed on the indi-
cator variables for AEs, and Poisson regression will be
used for the number of AEs. Gender, age, diagnostic
group and investigational site will be included as covari-
ates in all analyses.
Safety reporting
Investigators are responsible for monitoring the safety of
patients who have entered this study and for alerting the
representative of the sponsor to any event that seems
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unusual. The investigator is responsible for appropriate
medical care of patients during the study.
Reporting to study participants (parents and patients)
The sponsor (Radboud University Medical Centre,
Nijmegen, Prof. Dr. J. K. Buitelaar) or the respective
representative at each study centre will take responsi-
bility to report serious adverse events (SAEs) to the
regulatory bodies and Ethical Review Boards (ERBs)
in the countries as well as to investigators involved in
this study, if applicable in close collaboration with the
contract research organisation involved in this study.
Adverse and serious adverse events
AEs are defined as any undesirable experience occurring
to a subject during the study, whether or not considered
related to the study. ‘A serious adverse event (experi-
ence) or reaction is any untoward medical occurrence
that at any dose: results in death, is life-threatening, re-
sults in persistent or significant disability/incapacity, or
is a congenital anomaly/birth defect, or requires in-
patient hospitalisation or prolongation of existing hospi-
talisation’ [72]. The participating study centres comply
with national guidelines for procedures in the case of
(S)AEs, and these rules will be followed in case an
AE occurs. All AEs occurring during the visit of the
participant to the test site, or reported spontaneously
by the patient or parent, or observed by the investiga-
tor or his staff will be recorded. All AEs will be
followed until they have abated, or until a stable situ-
ation has been reached. Depending on the event,
follow-up may require additional tests or medical pro-
cedures as indicated, and/or referral to a general
physician or medical specialist.
Withdrawal of individual subjects
Patients can leave the study at any time for any reason if
they or their parents wish to do so without any conse-
quences. The investigator can decide to withdraw a sub-
ject from the study for urgent medical reasons. Study
participation will also be cancelled if patients do not
comply with the general directives of the study proce-
dures, or if the investigator decides it is in the best inter-
est of the subject (medical-ethical considerations).
The participating centres have considerable experience
with the type of research in paediatric populations pro-
posed in this protocol, and there are limited risks associ-
ated with this kind of research.
Premature termination of the project
If the project is terminated prematurely, for whatever
reason, the accredited/responsible ERB(s) and/or regula-
tory agencies will be notified immediately. The investiga-
tor will inform the patients and parents plus the
reviewing accredited/responsible ERB and/or regulatory
agencies if anything occurs, on the basis of which it ap-
pears that the disadvantages of participation may be sig-
nificantly greater than was foreseen in the research
proposal. The study will be suspended pending further
review by the accredited ERB/regulatory agencies, except
insofar as suspension would jeopardise the patients’
health. The investigator will take care that all patients/
parents are kept adequately informed.
Ethical considerations
This study will be conducted according to the principles
of the Declaration of Helsinki, version of 2008, and in
accordance with the Medical Research Involving Human
Subjects Act (WMO, as well as according to the ICH
GCP Guideline E6 (1996), EU Directive 2001/20/EC and
applicable regulatory requirements and guidelines in the
participating countries/regions.
The study received ethical approval from the ethical
committee in Mannheim, Germany (Medizinische Ethik-
kommission II, Medizinische Fakultät Mannheim der
Universität Heidelberg, Germany) on 15 January 2015.
Mannheim represents the leading and coordinating site.
Further applications for ethical approvals were made in
the UK (National Research Ethics Service Committee
London – Camberwell St Giles) and in the Netherlands
(CMO (Commissie Mensgebonden Onderzoek) Regio
Arnhem-Nijmegen). Recruitment in any centre will not
begin until local ethical approvals have been obtained in
addition to the ethical approval of the leading site in
Mannheim.
Benefits and risks assessment, group relatedness
The risks and discomforts of this study are estimated as
low. Any AE will be observed and addressed (e.g. by
dose adjustment or early discontinuation from the study
if clinically indicated).
Handling and storage of data and documents
All study data will be handled confidentially. Each par-
ticipant will get a code number which will be used to
store all data linked to participation in the study and un-
linked to demographic data (name, address, etc). The list
linking the code numbers to the demographic data will
be stored by the principal investigator. All data from all
sites will be stored in a secured web-based database.
Original data of all source documents will be retained
for a period of at least 15 years after report of the study
has been finalised. After analysis, any leftover material of
biological nature will be stored at −20 °C or −80 °C (as
appropriate) at the analysis location until 25 years after
the study is finished. The key to the identity of partici-
pants will only be available to the principal investigators.
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End of study report
The investigator will notify the accredited ERB of the
end of the study within a period of 8 weeks. The end of
the study is defined as the last patient’s last visit. In case
the study is ended prematurely, the investigator will no-
tify the accredited ERB, including the reasons for the
premature termination.
Within 1 year after the end of the study, the investiga-
tor/sponsor will submit a final study report with the re-
sults of the study, including any publications/abstracts of
the study, to the accredited ERB.
Public disclosure and publication policy
Findings from the present study are to be published in
international, peer-reviewed scientific journals and pre-
sented at international conferences.
Discussion
Based on the findings from the preclinical animal and hu-
man investigations within the TACTICS project, the
planned proof-of-concept clinical study will allow pilot-
testing of a (new) promising compound in children and ad-
olescents with OCD or ASD. Drug treatment for children
and adolescents with these indications has been a challen-
ging issue because there have only been few placebo-
controlled studies with glutamatergic compounds so far. In
general, there is a lack of solid information on the effects of
these drugs in children and adolescents; therefore, placebo-
controlled studies will contribute to determine the tolerabil-
ity/safety and efficacy/effectiveness in this population.
Due to a very limited budget as one of multiple pro-
jects within the TACTICS study, several cost-saving
measures and solutions had to be implemented in the
GOAT study design reflecting the pilot character of this
study but not limiting scientific quality or jeopardising
patients’ safety. This challenge has also been previously
noted in other projects funded by the European Union,
e.g. the Paediatric European Risperidone Studies (PERS)
[73]. In TACTICS GOAT, e.g. interpretations of ECG and
blood sample analyses as well as site monitoring will be
performed locally at each study centre by qualified special-
ists rather than by a centralised system or clinical research
organisation, respectively. This will be coordinated cen-
trally by the leading study centre and performed in ac-
cordance with Standard Operating Procedures (SOP) for
all sites. Furthermore, the pharmaceutical company H.
Lundbeck A/S, Copenhagen, Denmark, became a member
of the TACTICS consortium and will provide the medica-
tion free of charge. Cooperation between academia and
pharmaceutical companies is one of the overarching ob-
jectives of European Union-funded projects. For packing,
blinding, drug accountability and labelling we were able to
find a collaborator in the Clinical Trials Unit of the Phar-
macy at the University Hospital Heidelberg which
supports investigator-initiated and publicly funded trials
in a cost-saving yet professional manner.
Patients treated with glutamatergic compounds and
their parents will have the benefit of potential medication
effects on their symptomatology and the related burden of
illness (reductions), plus of respective improvements in
health-related quality of life. Equally important, all pa-
tients and parents can benefit from the high frequency
and intensity of care – offered via the study visits by expe-
rienced child and adolescent psychiatry staff – that in gen-
eral clearly extends beyond routine care settings.
An acute treatment period of as long as 12 weeks was
chosen in order to increase the chance to reflect change/
improvement based on medication treatment. With ap-
plying the respective adequate instruments, clinical out-
come parameters will reflect compulsivity symptom
clusters, but also comprehensive information on psycho-
social functioning and health-related quality of life rele-
vant in child and adolescent development. Contrasting
findings across the patient populations will allow the as-
sessment of disorder-related variation.
It is believed that the proposed project – with per-
forming this pilot clinical trial in populations of children
and adolescents with compulsivity disorders – will help
to elucidate efficacy/effectiveness and tolerability/safety
of glutamatergic medications, further to explore effects
of moderating and mediating factors on the response to
these compounds. Also, findings will allow assessment
of medication effects on biomarkers and neural mecha-
nisms underlying compulsivity. In addition, these pilot
data will be made available to be used for potential fu-
ture Paediatric Use Marketing Authorisation (PUMA)
directed trial applications.
Respective MRI/MRS findings (from subgroups of pa-
tients, combined with the data from the TACTICS pro-
ject’s COMPULS study) will help to clarify which
mechanisms count for the compulsive behaviours in the
considered disorders and subsequently to understand
the links between compulsivity, impulsivity and addic-
tion. These understandings will provide a basis for pro-
spectively developing a guide for clinicians as to whether
children are at high risk for negative outcome as severe
compulsive behaviours and addictive behaviours in ado-
lescence and adulthood.
Trial status
At the time of manuscript submission, ERB approval for
the leading site at the Central Institute of Mental Health
in Mannheim, Germany (15 January 2015) plus German
regulatory agency approval (BfArM, 26 June 2015) have
been obtained. Recruitment of first patients into the trial
is planned to begin in the second quarter of 2016.
This article is based on protocol version .01, 31 July 2014.
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